Affinity carrier using mutant VHH antibody
Provision of an affinity carrier using a mutant VHH antibody. An affinity carrier comprising: a solid phase carrier; and an immunoglobulin-binding protein bound to the solid phase carrier; wherein the immunoglobulin-binding protein comprises a mutant VHH antibody or a fragment of the mutant VHH antibody that recognizes an epitope in at least one region selected from the group consisting of amino acids 127 to 184 of SEQ ID NO: 22 and amino acids 13 to 210 of SEQ ID NO: 23.
1. An affinity carrier, comprising:
a solid phase carrier; and
an immunoglobulin-binding protein bound to the solid phase carrier,
wherein the immunoglobulin-binding protein comprises a mutant VHH antibody, or a fragment thereof, comprising a polypeptide having at least 90% identity to the amino acid sequence of SEQ ID NO: 1, the polypeptide has the CDR1 and CDR2 amino acid sequences of SEQ ID NO: 10 and SEQ ID NO: 11, respectively, corresponding to amino acids 26 to 35 and 51 to 65 of SEQ ID NO: 1, the polypeptide has the CDR3 amino acid sequence of SEQ ID NO: 12 corresponding to amino acids 96 to 107 of SEQ ID NO: 1, in which at least at one position selected from the group consisting of amino acids 97, 100, and 102 of SEQ ID NO: 1 has been substituted with histidine, and the immunoglobulin-binding protein binds to an Fab domain of trastuzumab.
2. The affinity carrier according to claim 1 , wherein the immunoglobulin-binding protein comprises a polypeptide selected from the group consisting of SEQ ID NOS: 5, 6, 7 and 8.
3. An affinity carrier, comprising:
a solid phase carrier; and
an immunoglobulin-binding protein bound to the solid phase carrier,
wherein the immunoglobulin-binding protein comprises a mutant VHH antibody, or a fragment thereof, comprising a polypeptide having at least 90% identity to the amino acid sequence of SEQ ID NO: 1, the polypeptide has at least one position selected from the group consisting of amino acids 43, 53, 64, 75, and 86 of SEQ ID NO: 1 substituted with arginine and retains the CDR1, CDR2, and CDR3 amino acid sequences of SEQ ID NO: 10, SEQ ID NO: 11, and SEQ ID NO: 12, respectively, corresponding to amino acids 26 to 35, 51-65, and 96-107 of SEQ ID NO: 1 except for any substitution at amino acid positions 53 and 64 in CDR2, and the immunoglobulin-binding protein binds to an Fab domain of trastuzumab.
4. The affinity carrier according to claim 3 , wherein the immunoglobulin-binding protein comprises the polypeptide of SEQ ID NO: 9.